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DFM and CO'K conceived the study. All authors made a substantial contribution to the protocol development. All authors have read and approved the manuscript.

The Wellcome Trust Health Innovation Challenge Fund \[Reference 106939/Z/15/Z\] and the Research and Development Division of the Public Health Agency (Northern Ireland) will provide research costs for the REALIST study. The funders have no role in the study design, data acquisition, data analysis or manuscript preparation.

Orbsen have granted a non-exclusive, trial-specific licence to the Cellular and Molecular Therapies Division of the National Health Service Blood and Transplant Service to manufacture REALIST ORBCEL-C to GMP standards for the REALIST trial. Orbsen have no role in the study design, data acquisition, data analysis or manuscript preparation.

The investigator team will have full access to the final trial dataset. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The results of the trial will be published when data on the primary outcome are available. Long term data and mechanistic data will also be reported though may form the basis of separate publications. Publications will be published in peer-reviewed open access journals (in keeping with the Wellcome Trust open access policy). A lay person's summary of the principal findings of the results will be sent to all patients involved in the study at their request.

This trial has received ethics approval from the REC (North East York REC). Reference 18/NE/006. Favourable opinion received 6^th^ February 2018. REC approval for amended protocol (v4.0 23.03.2020) received 27^th^ March 2020.

Informed consent will be obtained in accordance with the ethical principles which have their origin in the Declaration of Helsinki. Due to the incapacitating nature of the condition of participants in this trial, consent will be sought from either a Personal Legal Representative (PerLR) or Professional Legal Representative (ProLR). Given visiting restrictions in place during the COVID-19 pandemic provisions are in place to obtain verbal agreement from the PerLR via telephone. When participating patients regain capacity to understand the details of the trial, consent to continue participation in the study will be sought. Patients may withdraw or be withdrawn (by PerLR or ProLR) from the trial at any time without prejudice.
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